1
Country: USA | Funding: $1B
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
2
Country: USA | Funding: $640.6M
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
3
Country: USA | Funding: $614.6M
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
4
Country: USA | Funding: $284.6M
Lyndra Therapeutics is a developer of a novel therapeutic platform designed to sustain extended drug release in oral dosage form.
Lyndra Therapeutics is a developer of a novel therapeutic platform designed to sustain extended drug release in oral dosage form.
5
Country: Czech Republic | Funding: $3M
Mindpax is a digital technology company that helps people who suffer from bipolar affective disorder and schizophrenia
Mindpax is a digital technology company that helps people who suffer from bipolar affective disorder and schizophrenia
